Key Points Rhythm Pharmaceuticals presented real-world and Phase 3 data on setmelanotide in children with acquired hypothalamic obesity at ESPE 2026. A French early-access analysis…
September 10, 2026
September 10, 2026
Oncolytics Reports Preclinical Support for Pelareorep Plus Pan-RAS Inhibitor in Colorectal Cancer
Key Points Oncolytics Biotech reported preclinical results evaluating pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the study’s initial every-other-day pelareorep…
September 09, 2026
Actuate Reports Preclinical Synergy for Elraglusib With RAS Inhibitors in Pancreatic Cancer
Key Points Actuate Therapeutics reported preclinical data showing that elraglusib enhanced the activity of two investigational RAS-targeted therapies in pancreatic cancer models. The studies tested…
September 09, 2026
Kazia Doses First Patient in Phase 2 Paxalisib Trial for Recurrent AT/RT Brain Cancer
Key Points Kazia Therapeutics dosed the first patient in PNOC035, a Phase 2 study of paxalisib plus gemcitabine for recurrent or progressive AT/RT. The study…
Key Points Opus Genetics reported positive early data from five patients treated with OPGx-BEST1 in a Phase 1/2 study of inherited BEST1-related retinal diseases. All…
Key Points Serina Therapeutics advanced its SER-252 Phase 1b study to Cohort 2 after an independent safety committee reviewed blinded data from the first patient…
September 08, 2026
Compass Pathways Launches TRD Education Campaign at Psych Congress 2026
Key Points Compass Pathways will introduce its U.S. healthcare-provider education campaign, Change the Tune in TRD, at Psych Congress 2026 in New Orleans. The campaign focuses…
Key Points Adlai Nortye dosed the first patient in Australia in a global Phase 1 trial of AN4035. The U.S. FDA cleared the company’s IND…
September 04, 2026
Immuron Expands U.S. Digestive Health Portfolio With PROIBS Launch
Key Points Immuron Limited signed an exclusive U.S. distribution agreement with Calmino Group AB for PROIBS®. PROIBS is a European-certified medical device designed to address…
Key Points Compass Pathways was named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech, and Fierce Healthcare. The recognition highlights organizations and…
September 01, 2026
Ocugen Launches Pivotal Gene Therapy Trial for Vision-Threatening Geographic Atrophy
Key Points Ocugen has dosed the first patient in ArMaDa3, its global Phase 3 registrational trial of OCU410 for geographic atrophy caused by dry age-related…
September 01, 2026
MIRA-55 Moves Closer to IND as MIRA Completes Key Toxicology Studies
Key Points MIRA Pharmaceuticals completed seven-day dose-range finding toxicology and toxicokinetic studies of its oral, non-opioid inflammatory-pain candidate, MIRA-55, in rats and dogs. The studies…